Telehealth monitoring for patients with inflammatory bowel disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial evaluates the impact of a nurse-led telehealth monitoring program on medication adherence, self-efficacy, and quality of life in individuals with inflammatory bowel disease (IBD). Participants will be randomly assigned to either an intervention group receiving a structured telehealth program or a control group receiving standard care. The intervention includes educational materials, video content, group sessions, and regular phone calls over a 12-week period. Outcomes will be assessed using validated tools at baseline and after the intervention to determine effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 18 years or older
* Individuals aged 18 years or older
* Able to read and write in Turkish
* Diagnosed with inflammatory bowel disease (IBD) for at least 6 months
* In clinical remission (Harvey-Bradshaw Index score \< 5 or Simple Clinical Colitis Activity Index score \< 3)
* Able to use a smartphone
* Have access to an online messaging application (e.g., WhatsApp) and a valid e-mail address
* Capable of downloading and using a mobile or computer-based video conferencing application (e.g., Zoom)
* Willing to participate in the study voluntarily

Exclusion Criteria:

* Diagnosed with any psychiatric or cognitive disorder
* Having any condition that impairs communication
* Pregnant women
* Patients receiving infusion-based treatment
* Having an advanced chronic disease

Where it's running

• Istanbul University - Cerrahpasa Cerrahpaşa Faculty of Medicine Department of Gastroenterology
  Istanbul, Turkey (Türkiye) Recruiting

Study contacts

• Principal investigator: Kimya Kılıçaslan, PhD Candidate — Istanbul University - Cerrahpasa Institute of Graudate Studies
• Study coordinator: Kimya Kılıçaslan, PhD Candidate
• Email: kimya.kilicaslan@iuc.edu.tr
• Phone: +90 535 083 45 53

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DISC-0974-201 for adults with IBD-related anemia

  This Phase 2 trial will test whether DISC-0974-201 helps adults with inflammatory bowel disease who have anemia driven by inflammation.

  Recruiting at 15 sites Phase 2 Disc Medicine, Inc · Birmingham, Alabama and 14 other locations · NCT07368972

• Moderate breathing and movement: Can regular exercise help people with quiescent inflammatory bowel disease feel better?

  This trial tests whether a moderate-intensity exercise program improves quality of life for adults with Crohn's disease or ulcerative colitis who are currently in clinical remission.

  Recruiting Mahidol University · Bangkok Noi, Bangkok · NCT07775794

• Mediterranean Diet and Time-Restricted Feeding in Ulcerative Colitis in Remission

  This study tests whether a Mediterranean diet, with or without an 8-hour eating window, helps gut health and quality of life in adults with ulcerative colitis in remission.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago, Santiago Metropolitan · NCT07752446

• Screening for lipid disorders in children and teens with chronic diseases to flag cardiovascular risk

  This study tests a blood test and a questionnaire to screen children and teens with chronic conditions for lipid metabolism disorders and familial hyperlipidemia.

  Recruiting Jena University Hospital · Jena · NCT07716488

• Wearable data to spot IBD flareups in people with ulcerative colitis or Crohn's disease

  This study tests whether heart‑rate variability from participants’ own wearables can help predict IBD flares.

  Recruiting at 2 sites Maastricht University Medical Center · 's-Hertogenbosch and 2 other locations · NCT07647640

• PVT401 in healthy adults

  This trial will test intravenous PVT401 in healthy adults who carry the HLA DRB4*0101 or DRB4*0103 allele to see how the drug behaves in the body and whether single and multiple doses are safe.

  Recruiting Phase 1 Parvus Therapeutics, Inc. · Melbourne, Victoria · NCT07423000

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.